The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited (Target) by Torrent Pharmaceuticals Limited (Acquirer) with voluntary modifications. The Acquirer is the flagship company of the Torrent group and manufactures and sells pharmaceutical formulations (FDFs). The Target manufactures and markets FDFs and Active Pharmaceutical Ingredients (APIs) and provides Contract Development and Manufacturing Organisation (CDMO) services. The acquisition involves the Torrent Pharmaceuticals Limited acquiring shareholding in J. B. Chemicals & Pharmaceuticals Limited and the subsequent amalgamation of the Target with the Acquirer, subject to compliance of voluntary modifications offered by the Parties. The announcement was made on 21 OCT 2025 7:21PM by PIB Delhi. The release ID is 2181329. A detailed order from the Commission will follow.
Key Entities Referenced
Competition Commission of India: Regulator approving the acquisition.
Proposed Combination: Acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited.
J. B. Chemicals & Pharmaceuticals Limited: The target company in the acquisition.
Torrent Pharmaceuticals Limited: The acquirer company in the acquisition.
Competition Commission of India
CCI approves acquisition of J. B. Chemicals &
Pharmaceuticals Limited by Torrent Pharmaceuticals
Limited with voluntary modifications
Posted On: 21 OCT 2025 7:21PM by PIB Delhi
The Competition Commission of India has approved the proposed acquisition of J. B. Chemicals &
Pharmaceuticals Limited by Torrent Pharmaceuticals Limited with voluntary modifications.
The proposed combination relates to acquisition of shareholding by Torrent Pharmaceuticals Limited
(Acquirer) in J. B. Chemicals & Pharmaceuticals Limited (Target) and the subsequent amalgamation of the
Target with the Acquirer (Proposed Combination) (Acquirer and Target are collectively the ‘Parties’).
The Acquirer is the flagship company of the Torrent group and is inter alia engaged in the business
of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments.
The Target is inter alia engaged in business of manufacturing and marketing of diverse range of
FDFs and Active Pharmaceutical Ingredients (APIs) and also provides Contract Development and
Manufacturing Organisation (CDMO) services.
The Commission approved the Proposed Combination subject to compliance of voluntary
modifications offered by the Parties.
Detailed order of the Commission will follow.
*****
NB/AD
(Release ID: 2181329)